NEW YORK (GenomeWeb) – Agendia said today that French hospital group Unicancer has selected its MammaPrint and BluePrint tests for use in a group of 18 comprehensive cancer centers.

The agreement includes centralized testing performed by Agendia in its CLIA-certified, CAP-accredited Amsterdam lab, as well as the provision of next-gen sequencing MammaPrint BluePrint kits, which hospital labs can run in house.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.